| 000 | 01821 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250514064533.0 | ||
| 264 | 0 | _c20030515 | |
| 008 | 200305s 0 0 eng d | ||
| 022 | _a1521-6616 | ||
| 024 | 7 |
_a10.1016/s1521-6616(02)00049-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCetkovic-Cvrlje, Marina | |
| 245 | 0 | 0 |
_aTargeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice. _h[electronic resource] |
| 260 |
_bClinical immunology (Orlando, Fla.) _cMar 2003 |
||
| 300 |
_a213-25 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdoptive Transfer |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCytokines _xbiosynthesis |
| 650 | 0 | 4 |
_aDNA-Binding Proteins _xmetabolism |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 1 _xprevention & control |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aInterleukin-2 _xpharmacology |
| 650 | 0 | 4 | _aJanus Kinase 3 |
| 650 | 0 | 4 |
_aLymphocyte Activation _xdrug effects |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred C57BL |
| 650 | 0 | 4 | _aMice, Inbred NOD |
| 650 | 0 | 4 | _aMilk Proteins |
| 650 | 0 | 4 |
_aOvalbumin _ximmunology |
| 650 | 0 | 4 | _aPhosphorylation |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aQuinazolines _xpharmacology |
| 650 | 0 | 4 | _aSTAT5 Transcription Factor |
| 650 | 0 | 4 |
_aT-Lymphocytes _xdrug effects |
| 650 | 0 | 4 |
_aTrans-Activators _xmetabolism |
| 650 | 0 | 4 |
_aTyrosine _xmetabolism |
| 700 | 1 | _aDragt, Angela L | |
| 700 | 1 | _aVassilev, Alexei | |
| 700 | 1 | _aLiu, Xing-Ping | |
| 700 | 1 | _aUckun, Fatih M | |
| 773 | 0 |
_tClinical immunology (Orlando, Fla.) _gvol. 106 _gno. 3 _gp. 213-25 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s1521-6616(02)00049-9 _zAvailable from publisher's website |
| 999 |
_c12497854 _d12497854 |
||